Background and objectives COVID‐19 convalescent plasma (CCP) has been used,
predominantly in high‐income countries (HICs) to treat COVID‐19; available data suggest …

Background and objectives Use of convalescent plasma for coronavirus disease 2019
(COVID‐19) treatment has gained interest worldwide. However, there is lack of evidence on …

Low-and middle-income countries (LMICs) remain neglected in the Coronavirus 19 (COVID-
19) pandemic. COVID-19 convalescent plasma (CCP)(ie plasma collected from individuals …

2. METHODS The AABB Board of Directors commissioned a committee of experts to draft
clinical practice guidelines for the use of CCP. The primary focus was to evaluate whether …

The collection and clinical use of COVID-19 convalescent plasma (CCP) as a therapy for
COVID-19 infection is under development and early use in many centers worldwide. We …

As transfusion medicine specialists we understood the potential that convalescent plasma
(CCP) could play early in the management of patients with COVID-19. However, with no …

In this issue of Transfusion Medicine Reviews, we are pleased to offer readers an
assessment as of April 2020 of COVID-19 convalescent plasma (CCP) by H Cliff Sullivan …

The pandemic caused by the novel coronavirus, called SARS-CoV-2, affected more than
one million people around the world. The COVID-19, the acronym derived from the …

As the coronavirus disease (COVID-19) pandemic led to a global health crisis, there were
limited treatment options and no prophylactic therapies for those exposed to severe acute …

Most high-income countries are aggressively engaged in the collection and research
evaluation of convalescent plasma as a specific passive immunotherapy for treatment of …